Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections (ACCUTE)

What is the purpose of this trial?

The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections receiving standard of care therapy.


Participation Guidelines

Ages: 12 years and older

Gender: Both


Atox Bio

Dates: 10/26/2015 - 09/30/2017

Last Updated: 08/03/2016

Study HIC#: 1507016217

Get Involved

For more information about this study, contact:
Casey Hill
+1 203-688-3878
casey.hill@ynhh.org

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image